Waldenstrom macroglobulinemia
Advertisement
Waldenström macroglobulinemia (WM) is a rare blood malignancy characterized by abnormal white blood cells in the bone ...
According to a study that reviewed response and survival outcomes in Waldenström macroglobulinemia (WM) patients who ...
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as a ...
A mixed-method study of Dutch patients, presented at the 63rd American Society of Hematology Annual Meeting & ...
A study that reviewed response and survival outcomes in Waldenström macroglobulinemia (WM) patients who underwent ...
In a study conducted presented at the 2021 American Society of Hematology Annual Meeting, researchers led by Aisha S. ...
Second-generation oral Bruton tyrosine kinase (BTK) inhibitor tirabrutinib demonstrated sustained efficacy in ...
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
Patients with treatment-naïve Waldenström macroglobulinemia (WM) who receive frontline immunochemotherapy have ...
Treatment with zanubrutinib was well tolerated and associated with high clinical activity in patients with ...
A novel idiotype (scFv-CCL20) DNA vaccine was associated with favorable perturbation of the immune microenvironment in ...
The use of NSC12, a novel small molecule that specifically halts the FGF/FGFR axis in Waldenstrom macroglobulinemia ...
A real-world retrospective analysis found old age, low platelet count, low albumin, high β-2 microglobulin, high ...
Patients with Waldenstrom macroglobulinemia (WM) who present with characteristics suggestive of a concomitant ...
Since 2006, clinicians treating Waldenstrom macroglobulinemia (WM) have shifted away from using chlorambucil as ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
First-line treatment with bortezomib (B) plus dexamethasone, rituximab, and cyclophosphamide (DRC) was well tolerated ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.